Posts

A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma

/by

Authors: Susan Short, Christopher Twelves, Lucy Brazil, Catherine McBain, et al
Clinicaltrials.gov, 11 August 2016
—
An open-label phase to assess the frequency and severity of adverse events in recurrent glioblastoma patients receiving Sativex in combination with dose-intense Temozolomide (Part A). A randomisation phase to assess the safety of Sativex compared with placebo (Part B). Patient…

Read more

Spontaneous regression of septum pellucidum/forniceal pilocytic astrocytomas–possible role of Cannabis inhalation.

/by

Authors: Mansoor Foroughi, Glenda Hendson, Michael A. Sargent, Paul Steinbok
Child’s Nervous System, DATE
—
INTRODUCTION: Spontaneous regression of pilocytic astrocytoma after incomplete resection is well recognized, especially for cerebellar and optic pathway tumors, and tumors associated with Neurofibromatosis type-1 (NF1). The purpose of this report is to document spontaneous reg…

Read more

Cannabinoid receptors in human astroglial tumors.

/by

Authors: Janka Held‐Feindt, Lutz Dörner, Gülcan Sahan,H. Maximilian Mehdorn, Rolf Mentlein
Journal of Neurochemistry, August 2008
—
In animal models, cannabinoids are reported to inhibit the growth of tumors, including gliomas. These effects have been claimed to be mediated via cannabinoid receptors 1 and 2 (CB1, CB2). To elucidate a possible relevance for treatment of human gliomas, we investigated recept…

Read more